| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests |
| 14 Sep 2026 |
8-K: Regulation FD Disclosure
Beginning on September 14, 2026, representatives of Caris Life Sciences, Inc. (the “Company”) intend to use an investor presentation (the “Investor Presentation”) in meetings with current and potential investors at the Morgan Stanley 24t... |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
Revenue growth of 45% driven by strong performance in molecular profiling services, including approximately 59,200 clinical cases, consisting of over 114,000 whole exome/whole transcriptome tests with over 345,000 total oncology tests |
| 05 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
Caris Life Sciences, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders on June 4, 2026 (the “2026 Annual Meeting”). The Company’s shareholders were asked to vote on two proposals, each as more fully described in the Compa... |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
Revenue growth of 79% driven by strong performance in molecular profiling services |
| 02 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
On April 1, 2026 (the “Closing Date”), Caris Life Sciences, Inc., a Texas corporation (the “Company”) entered into a Financing Agreement, dated as of the Closing Date (the “New Credit Agreement”), by and among the Company, as borrower, c... |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Full year revenue growth of 97% driven by strong performance in molecular profiling services |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Full year revenue growth of approximately 94% driven by strong performance in molecular profiling services |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Revenue growth of 113% driven by strong performance in molecular profiling services |
| 30 Oct 2025 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1.1.Registered Office. The address of the registered office of Caris Life Sciences, Inc. (the “Corporation”) in the State of Texas, and the name of its registered agent at such address, shall be as set forth in the Corporation’s ... |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
IRVING, Texas, August 12, 2025— Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025. |
| 20 Jun 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events
Section 1.1. Registered Office. The address of the registered office of Caris Life Sciences, Inc. (the “Corporation”) in the State of Texas, and the name of its registered agent at such address, shall be as set forth in the Corporation’s... |
Loading...